<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131296</url>
  </required_header>
  <id_info>
    <org_study_id>MicroFlu</org_study_id>
    <nct_id>NCT04131296</nct_id>
  </id_info>
  <brief_title>Lung Bacteriobiota and Influenza Mortality</brief_title>
  <acronym>MicroFlu</acronym>
  <official_title>Association of Lung Bacteriobiota With Intensive Care Unit Mortality in ARDS Patients: MicroFlu Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza is a potentially lethal disease still responsible for thousands excess deaths both
      in Europe and the United States. Despite the use of neuraminidase inhibitors, its treatment
      is mostly based on symptomatic care. Lung microbiota has been shown to be involved in the
      immunity against influenza and is correlated with lung inflammation in numerous chronic
      respiratory diseases. We therefore aim to analyse the correlation between lung bacteriobiota
      and influenza ICU mortality
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza is a viral disease which is still responsible for thousands of excess deaths par
      year both in Europe and in the US. Despite the use of neuraminidase inhibitors, its treatment
      is mostly based on symptomatic care. As lung microbiota is correlated with lung inflammation
      in numerous chronic respiratory diseases, we hypothesize that lung microbiota would be
      correlated with influenza outcomes. In a pilot study, we found that lung bacteriobiota but
      not mycobiota is associated with influenza ICU mortality. We therefore aim to confirm this
      correlation between lung bacteriobiota and influenza mortality.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lung bacteriobiota and ICU mortality</measure>
    <time_frame>at admission</time_frame>
    <description>Comparison of lung bacteriobiota alpha diversity between influenza ICU survivors and non-survivors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung bacteriobiota and ICU mortality</measure>
    <time_frame>at admission</time_frame>
    <description>Analysis of lung bacteriobiota beta diversity between influenza ICU survivors and non-survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung bacteriobiota and 7-day mortality</measure>
    <time_frame>at admission</time_frame>
    <description>Analysis of lung bacteriobiota beta diversity between influenza 7-day survivors and non-survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteria and ICU mortality</measure>
    <time_frame>at admission</time_frame>
    <description>Association of bacteria with influenza ICU mortality by LefSe method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteria and 7-day mortality</measure>
    <time_frame>at admission</time_frame>
    <description>Association of bacteria with influenza 7-day mortality by LefSe method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality based on Shannon index</measure>
    <time_frame>at admission</time_frame>
    <description>Comparison of ICU mortality based on a threshold of 1.79 for Shannon Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung bacteriobiota and 7-day mortality</measure>
    <time_frame>at admission</time_frame>
    <description>Comparison of lung bacteriobiota alpha diversity between influenza 7-day survivors and non-survivors</description>
  </secondary_outcome>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Influenza</condition>
  <condition>Critical Illness</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>influenza screening</intervention_name>
    <description>positive influenza screening</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      sputum or tracheal aspirate
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Influenza patients admitted to ICU
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient above 18 year-old admitted to intensive care unit

          -  Influenza diagnosis by PCR or rapid diagnostic test

        Exclusion Criteria:

          -  Guardianship or curatorship

          -  Prisoners

          -  No health insurance

          -  No legal representative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical intensive care unit, Pellegrin hospital</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intensive care unit, CH Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bernard Gauche, MD</last_name>
      <email>bernard.gauche@ch-libourne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive care unit, CH Francois Mitterrand</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre Massri, MD</last_name>
      <email>alexandre.massri@ch-pau.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bordeaux</investigator_affiliation>
    <investigator_full_name>Dr Pauline Esteves</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>microbiota</keyword>
  <keyword>intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

